B Braun to distribute BSmart injection pressure monitor for PNBs

B. Braun Medical, the market leader in Regional Anaesthesia (RA),announced that it will become the exclusive US distributor of the BSmart injection pressure monitor for peripheral nerve blocks (PNBs) from Concert Medical, LLC. BSmart is the first disposable monitor for measuring of injection pressure during administration of PNBs.

“We want to be the customer’s first choice for delivering RA safely and effectively,” said Joe Cleary, group product director of pain control marketing at B.Braun. “In the coming months, B.Braun will highlight ways to integrate complementary monitoring modalities (injection pressure, ultrasound and stimulation) and share the benefits. We call it ISM, or Injection Safety Monitoring,” added Cleary.

Practitioners already document resistance to injection, however, objective pressure monitoring is a relatively new concept.

Sagent Pharma launches oxaliplatin

Sagent Pharmaceuticals, Inc. has introduced oxaliplatin injection, USP, an antineoplastic agent, now in two liquid presentations. According to IMS, for the 12 months ending July 2014, the US market for oxaliplatin approximated $102 million. As with all products in Sagent's portfolio, oxaliplatin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce the risk of medication errors.

Oxaliplatin injection, USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and for treatment of advanced colorectal cancer.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.